Loading...
EHA congress 20222025-01-28T17:17:00+01:00

ASCO/EHA 2022

Lecture Board: Othman Al-Sawaf, MD; Chan Cheah, MBBS, DMSc.; Naval Daver, MD; Shirley D’Sa, MD; Harry P. Erba, MD, PhD.; Wojciech Jurczak, MD, PhD.; Michael Wang, MD; Moshe Yair Levy, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downlaods from ASCO/EHA 2022

Slide Kit BTK inhibition in B-Cell Malignancies

ASCO EHA 2022 English

Full report (english)

EXPERT VIDEOS

All video interviews from ASCO/EHA 2022

Naval Daver overviews the most promising new agents in the treatment of AML, how existing drugs can blend into new regimens and how the prognosis of patients with AML will evolve in the years to come. Finally, he talks about risk factors for ICI-related pneumonitis development and if pneumonitis increases mortality in AML patients.

Jorge Castillo explains the most meaningful diagnostic criteria for WM, give insights into the “real-world” treatment of WM with zanubrutinib, bortezomib and other treatment strategies and how to sequence therapies in WM. He explains promising modes of action of new agents in the treatment of WM and depicts his personal highlights from this year’s EHA congress.

Wojciech Jurczak outlines what can be achieved with the current standard treatments in the setting of follicular lymphoma, which findings have been observed for PI3K inhibitor therapy in the TIDAL study and were we are today with respect to CAR-T cell therapy for patients with follicular lymphoma.

Constantine Tam highlights the most relevant findings presented at EHA 2022 as well as promising modes of action of new agents in the treatment of indolent lymphomas. He explains how resistance to BTK inhibitors can be addressed in B-cell malignancies while giving an outlook on a BTK protein degrader and finally summarizes the long-term results obtained with zanubrutinib compared to ibrutinib in the ASPEN trial in patients with WM.

Shirley D’Sa discusses how the treatment and especially the prognosis of patients with WM evolved over the last decades, which approaches can be used to successfully treat patients with MYD88WTWM, how the interaction between WM cells and the bone marrow microenvironment can be used to develop new ways to overcome treatment resistance and finally explains how often the Binge-Neel Syndrome happens, how its diagnosed and how it should be treated.

Go to Top